Trial Profile
A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Cytarabine; Mitoxantrone
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Oct 2012 New trial record